Importance

Loading Importance Indicators...

Abstract

In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form B), wherein the crystalline form has prominent peaks at 10.69, 17.17, 21.00 and 24.67 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. In another aspect, the invention relates to a preparation including the crystalline solid form (Form B), wherein the preparation includes additionally one or more additional crystalline solid forms of Alpha-1062 gluconate, including at least a crystalline solid form according to Form C, wherein Form C has prominent peaks at 3.90, 9.74, 10.35 and 21.43 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. Also disclosed are methods for treating a brain disease associated with cognitive impairment and/or with a cholinergic deficit in a subject, including administering the crystalline forms of Alpha-1062 gluconate to a subject in need thereof.

Loading the Abstract Image...

First Claim